# Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood

> **NCT02650206** · PHASE1 · COMPLETED · sponsor: **Stanford University** · enrollment: 56 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Diabetes Mellitus, Type II
- Diabetes Mellitus, Adult-Onset
- Inflammation

## Interventions

- **DRUG:** Victoza (liraglutide) with dietician monitoring
- **OTHER:** Placebo with dietician monitoring

## Key facts

- **NCT ID:** NCT02650206
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2019-09-27
- **Final completion:** 2019-09-27
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2020-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02650206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02650206, "Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02650206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*